APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate * Any T, any N, M0 * Received prior therapy comprising one of the following regimens for primary prostate cancer: * External beam radiotherapy * Brachytherapy with or without pelvic external beam radiotherapy * Cryosurgery * Radical prostatectomy with or without adjuvant or salvage radiotherapy * Adjuvant or salvage radiotherapy after radical prostatectomy is allowed provided the following criteria is met: * PSA was never greater than 6.0 ng/mL * At least 3 months since androgen deprivation * Elevated PSA (0.4-6.0 ng/mL) that has increased on 2 measurements taken at least 2 weeks apart * No history of or radiological evidence of current CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases) PATIENT CHARACTERISTICS: Performance status: * ECOG 0-1 Life expectancy: * At least 12 months Hematopoietic: * WBC greater than 2,500/mm\^3 * Absolute neutrophil count greater than 1,000/mm\^3 * Platelet count greater than 100,000/mm\^3 * No prior bleeding disorder Hepatic: * Bilirubin no greater than 2 times upper limit of normal (ULN) * AST no greater than 2 times ULN * Hepatitis B and C negative Renal: * Creatinine no greater than 2 times ULN * BUN no greater than 2 times ULN Cardiovascular: * No clinically significant cardiovascular disease * No New York Heart Association grade II-IV heart disease (symptomatic congestive heart failure) * No unstable angina pectoris * No serious cardiac arrhythmia requiring medication * No uncontrolled hypertension * No prior myocardial infarction * No grade II or greater peripheral vascular disease within the past year * No prior deep vein thrombosis Other: * Fertile patients must use effective contraception * HIV and HTLV I and II negative * No other uncontrolled illness, underlying medical condition, psychiatric illness, or social situation that would preclude study participation * No ongoing or active infection * No active autoimmune disease requiring treatment * No significant traumatic injury within the past 4 weeks * No serious nonhealing wound, ulcer, or bone fracture * No other "currently active" malignancy except nonmelanoma skin cancer * Not "currently active" if considered by physician as having less than 30% risk of relapse after completion of therapy PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior immunotherapy * No prior anti-vascular endothelial growth factor therapy Chemotherapy: * No prior chemotherapy Endocrine therapy: * No prior hormonal therapy (e.g., luteinizing hormone-releasing hormone \[LHRH\] agonists or antagonists, antiandrogens, estrogens, megestrol, or PC-SPES) for progressive disease * Prior hormonal therapy in adjuvant or neoadjuvant setting as primary therapy allowed if at least 3 months since androgen deprivation * No concurrent systemic steroid therapy (inhaled or topical steroids allowed) Radiotherapy: * No concurrent radiotherapy Surgery: * At least 4 weeks since prior major surgery, including open biopsy or needle biopsy of liver * No concurrent major surgery Other: * At least 10 days since prior aspirin * At least 10 days since prior oral or parenteral anticoagulants except to maintain patency of pre-existing permanent indwelling IV catheters * No concurrent aspirin * No concurrent oral or parenteral anticoagulants except to maintain patency of pre-existing permanent indwelling IV catheters * No other concurrent experimental or commercial agents or therapies for prostate cancer